Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study.

"DK reports honoraria from Takeda, Chugai, Lilly, MSD, Ono, Taiho, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer, and Merckbiopharma (research funding from Ono, MSD, Novartis, Servier, Janssen, IQVIA, Syneoshealth, and Cimicshiftzero). SM reports honoraria from Merck Seronobiopharma (research funding from Roche Diagnostics). TY reports receiving research funding from Taiho, Sumitomo Dainippon, Ono, Chugai, Amgen, Parexel International, MSD, Daiichi-Sankyo, and Sanofi. TK reports receiving research funding from MSD, Ono, Bristol-Myers Squibb, Astellas Amgen, Taiho, Chugai, and Shionogi, as well as honoraria from Ono, Bristol-Myers Squibb, MSD, Astellas, Merck, and Oncolys. MO, HF, KS, SS, and TF have nothing to disclose."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."